Any effect of CYP2C9 variants on warfarin clearance in Chinese patients? [1]

Thrombosis and Haemostasis

Volumn 97, Issue 5, 2007, Pages 866-868

  You, Joyce H S ^a   Zuo, Zhong ^a   Lo, Cindy M Y ^a   Zhou, Limin ^a   Yiu, Hillary H W ^a   Chau, Carrie T S ^a   Choi, Kai Chow ^b   Choi, David K M ^a   Wong, Raymond S M ^b   Cheng, Gregory ^b  

^a Chinese University of Hong Kong   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MENADIONE EPOXIDE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOSIDE REDUCTASE COMPLEX 1; WARFARIN;

ADULT; AGE DISTRIBUTION; ANTICOAGULATION; BLEEDING; BLOOD SAMPLING; CHINESE; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ETHNIC DIFFERENCE; FEMALE; FISHER EXACT TEST; GENETIC VARIABILITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; RANK SUM TEST; SEX DIFFERENCE; STUDENT T TEST;

AGE FACTORS; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; FEMALE; HONG KONG; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; STEREOISOMERISM; VARIATION (GENETICS); WARFARIN;

EID: 34249093270     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-04-0195     Document Type: Letter

References (17)

1. Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76:210-219.
2. Yuan HY, Chen JJ, Lee MTM, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751.
3. Chern HD, Ueng TH, Fu YP, et al. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 2006; 367: 108-113.
4. You JHS, Chan FWH, Wong RSM, et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 582-587.
5. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504.
6. Chan E, McLachlan A, O'Reilly R, et al. Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994; 56: 286-294.
7. Haber LT, Maier A, Gentry PR, et al. Genetic polymorphisms in assessing interindividual variability in delivered dose. Reg Toxicol Pharmacol 2002; 35: 177-197.
8. Veenstra DL, You JHS, Rieder MJ, et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 687-691.
9. Naidong W, Ring PR, Midtlien C, et al. Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma. J Pharm Biomed Anal 2001; 25: 219-226.
10. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-528.
11. Takahashi H, Wilkinson G, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-263.
12. Takahashi H, Ieiri I, Wilkinson GR, et al. 5′-Flanking region polymorphisms of CYP2C9 and their relationship, to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103: 3055-3057.
13. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphism in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 10 1-110.
14. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirement: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
15. Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75: 204-212.
16. Wynne H, Cope L, Kelly P, et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Pharmacol 1995; 40: 203-207.
17. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphism on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710.